ESSA Pharma, Inc.
(TSX Venture Exchange : EPIX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.49%34.650.9%$1168.91m
JNJJohnson & Johnson
0.62%131.350.7%$908.58m
MRKMerck & Co., Inc.
1.92%85.060.6%$797.24m
BMYBristol-Myers Squibb Company
2.67%46.971.4%$680.66m
ABBVAbbVie, Inc.
2.30%64.432.3%$610.53m
LLYEli Lilly and Company
0.24%110.491.0%$456.04m
NVSNovartis AG Sponsored ADR
0.99%89.460.2%$209.31m
AZNAstraZeneca PLC Sponsored ADR
0.39%44.351.2%$166.53m
GSKGlaxoSmithKline plc Sponsored ADR
0.60%40.200.3%$95.35m
NVONovo Nordisk A/S Sponsored ADR Class B
2.70%51.650.1%$81.50m
SNYSanofi Sponsored ADR
0.89%42.020.2%$56.34m
LCILannett Company, Inc.
4.31%6.7736.6%$10.92m
AKTXAkari Therapeutics Plc Sponsored ADR
-5.37%1.941.6%$3.62m
EPIXESSA Pharma Inc
3.28%1.510.1%$0.03m

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.